Regulus Therapeutics Inc (NASDAQ:RGLS) – Wedbush issued their Q1 2019 EPS estimates for Regulus Therapeutics in a report released on Tuesday, March 26th, Zacks Investment Research reports. Wedbush analyst L. Moussatos forecasts that the biopharmaceutical company will post earnings of ($0.69) per share for the quarter. Wedbush currently has a “Hold” rating and a $2.00 target price on the stock. Wedbush also issued estimates for Regulus Therapeutics’ Q2 2019 earnings at ($0.37) EPS, Q3 2019 earnings at ($0.53) EPS, Q4 2019 earnings at ($0.49) EPS, FY2019 earnings at ($2.09) EPS, Q1 2020 earnings at ($0.50) EPS, Q2 2020 earnings at ($0.52) EPS, Q3 2020 earnings at ($0.53) EPS, Q4 2020 earnings at ($0.55) EPS, FY2020 earnings at ($2.11) EPS, FY2021 earnings at ($2.38) EPS and FY2022 earnings at ($2.70) EPS.
A number of other analysts have also commented on RGLS. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Friday, March 29th. Wells Fargo & Co reduced their price target on shares of Regulus Therapeutics from $6.00 to $1.50 and set a “market perform” rating for the company in a research note on Tuesday, March 19th. Six analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Regulus Therapeutics has an average rating of “Hold” and a consensus target price of $1.31.
Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.06). Regulus Therapeutics had a negative return on equity of 671.46% and a negative net margin of 67,650.01%. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $7.01 million.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Wedbush Securities Inc. boosted its holdings in shares of Regulus Therapeutics by 32.8% in the first quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 10,751 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Regulus Therapeutics in the first quarter worth approximately $68,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Regulus Therapeutics by 396.3% in the third quarter. Renaissance Technologies LLC now owns 595,501 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 475,512 shares during the last quarter. 24.44% of the stock is currently owned by institutional investors.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Further Reading: Inflation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.